{
    "info": {
        "nct_id": "NCT04243616",
        "official_title": "Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer (CemiHALT )",
        "inclusion_criteria": "1. Pathologically proven diagnosis of invasive breast cancer, cT1-T3, cN0-N3, cM0, HR+ (ER+ and/or PR+) HER2 negative or HR- (ER- and PR-) HER2 negative/triple negative breast cancer.\n2. Tumors with positive PD-L1 and/or PD-L1 protein expression. Positivity is defined as PD-L1 and/or PD-L2 expression of ≥ 1% of immune cells within the stroma or in cancer cells.\n3. Estrogen and/or progesterone receptor positive tumor defined ≥1% positively staining cells by immunohistochemistry, according to the current American Society of Clinical Oncology (ASCO) / College of American Pathologists (CAP) guidelines.\n4. HER2/neu must be negative by immunohistochemistry (IHC) defined as IHC 0 or 1+ or fluorescence in situ hybridization (FISH) or other ISH methods with a ratio of < 2 according to current ASCO (American Society of Clinical Oncology)/CAP guidelines.\n5. Candidate for neoadjuvant chemotherapy due to their clinical stage or subtype of breast cancer as decided by the treating physician.\n6. Breast imaging with mammogram and/or ultrasound and/or MRI is per standard of care for diagnosis, but at least one modality of imaging must be completed within 30 days of registration.\n7. Systemic imaging with CT scan, bone scan, positron emission tomography (PET) scan or MRI if clinically indicated per treating physician's discretion.\n8. Left ventricular ejection fraction (LVEF) ≥ lower limit of normal (per institutional normal) determined by echocardiogram or nuclear medicine scan within 30 days of registration.\n9. The patient must be female.\n10. Age ≥18 years.\n11. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.\n12. The patient must provide study-specific informed consent prior to study entry.\n13. Patients with a prior history of contralateral breast cancer will be considered eligible, if they have completed all treatment (including endocrine therapy) more than two years prior to registration.\n14. Patients must not have had a prior treatment for this breast cancer or for any malignancy diagnosed or treated within the past two years, with the exception of non-melanomatous skin cancer, carcinoma in situ of the cervix and contralateral breast cancer, as described above.\n15. Patients with bilateral breast cancer are also eligible provided HER2 negativity is documented on both right and left breast cancer and patient is deemed to be a candidate for neoadjuvant chemotherapy by treating physician.\n16. Patients with multicentric or multifocal disease are eligible if they are a candidate for neoadjuvant chemotherapy.\n17. Patients must meet one of the following:\n\n    * Postmenopausal for at least one year before the screening visit, or\n    * Surgically sterile, or\n    * If they are of childbearing potential, negative pregnancy test within 14 calendar days prior to registration for women of childbearing potential\n    * Women of childbearing age must use at least two adequate methods of contraception during the treatment period and at least 6 months from the last dose of chemotherapy. Examples of contraceptives include barrier methods, intrauterine devices (IUDs) hormonal or copper, oral contraceptive pills, and abstinence. Hormonal methods are not to be used by patients with HR+ breast cancer.\n18. Adequate organ function with baseline lab values.\n\n    * Absolute neutrophil count (ANC) ≥ 1500/µL\n    * Hemoglobin (Hb) ≥ 8g/dL\n    * Platelet count ≥ 100,000/µL\n    * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3x institutional upper limit of normal (ULN)\n    * Serum bilirubin within ≤ 1.5 x ULN except patients with Gilbert's syndrome for whom the direct bilirubin should be within normal range.\n    * Creatinine clearance of ≥ 30 mL/min\n    * International normalized ratio (INR) and activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN. This applies to patients not receiving therapeutic anticoagulation. Patients on therapeutic anticoagulation should be on a stable dose.\n    * Thyroid-stimulating hormone (TSH) ≤ institutional ULN\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Patients with clinical or pathologically proven metastatic disease.\n2. HER2 positive disease as determined by either ISH or 3+ on IHC.\n3. Synchronous non-breast malignancy (exceptions include non-melanomatous skin cancer, carcinoma in situ of the cervix).\n4. Purely noninvasive breast cancer (i.e., ductal carcinoma in situ, lobular carcinoma in situ) without any concurrent invasive breast cancer\n5. Men with breast cancer. Male breast cancer is a rare event.\n6. Medical, psychiatric or other conditions that would prevent the patient from receiving the protocol therapy or providing informed consent.\n7. Pregnant or lactating women are ineligible.\n8. Treatment with any investigational drug within 30 days of registration. Prior treatment with any immunotherapy or chemotherapy for this breast cancer.\n9. Current grade ≥ 2 peripheral neuropathy (according to NCI CTCAE v. 5.0).\n10. Cardiopulmonary dysfunction defined as: Inadequately controlled angina, heart failure or serious cardiac arrhythmia not controlled by adequate medication.\n11. Active Hepatitis B defined as positive Hep B surface antigen (HBsAg) or Hepatitis C. Patients with previous hepatitis B virus (HBV) infection or resolved HBV infection (defined as having a negative HBsAg test and a positive antibody to hepatitis B core antigen [anti-HBc] antibody test) are eligible. If HBV DNA testing is positive, the patient is not eligible for study participation. Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.\n12. Positive test for HIV.\n13. History of symptomatic CHF⎯Grade ≥ 3 per NCI CTCAE v5.0 or New York Heart Association (NYHA) Class ≥ II.\n14. History of autoimmune disease, including but not limited to myasthenia gravis, autoimmune myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.\n\n    * Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible for this study.\n    * Patients with controlled Type 1 diabetes mellitus on a stable insulin regimen are eligible for this study.\n    * Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis) are eligible, provided the disease has no systemic manifestations and requires only low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%).\n15. Treatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor (TNF) agents) within 2 weeks prior to study entry, or anticipated requirement for systemic immunosuppressive medications during the study. Patients who have received acute, low-dose, systemic immunosuppressant medications equivalent to ≤ 10mg of prednisone within the 7 days prior to study entry (small dose of dexamethasone for nausea, short course for upper respiratory tract infection etc.) may be enrolled in the study.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "17. Patients must meet one of the following:",
            "criterions": [
                {
                    "exact_snippets": "Patients must meet one of the following:",
                    "criterion": "alternative eligibility criteria",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. The patient must be female.",
            "criterions": [
                {
                    "exact_snippets": "The patient must be female.",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Left ventricular ejection fraction (LVEF) ≥ lower limit of normal (per institutional normal) determined by echocardiogram or nuclear medicine scan within 30 days of registration.",
            "criterions": [
                {
                    "exact_snippets": "Left ventricular ejection fraction (LVEF) ≥ lower limit of normal (per institutional normal)",
                    "criterion": "left ventricular ejection fraction (LVEF)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0,
                                "unit": "lower limit of normal (per institutional normal)"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "determined by echocardiogram or nuclear medicine scan",
                    "criterion": "LVEF assessment method",
                    "requirements": [
                        {
                            "requirement_type": "assessment method",
                            "expected_value": [
                                "echocardiogram",
                                "nuclear medicine scan"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "within 30 days of registration",
                    "criterion": "timing of LVEF assessment",
                    "requirements": [
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days before registration"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "18. Adequate organ function with baseline lab values.",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "baseline lab values",
                    "criterion": "laboratory values",
                    "requirements": [
                        {
                            "requirement_type": "baseline",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Patients with a prior history of contralateral breast cancer will be considered eligible, if they have completed all treatment (including endocrine therapy) more than two years prior to registration.",
            "criterions": [
                {
                    "exact_snippets": "prior history of contralateral breast cancer",
                    "criterion": "prior history of contralateral breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "completed all treatment (including endocrine therapy) more than two years prior to registration",
                    "criterion": "completion of all treatment for contralateral breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "completion",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since completion",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Age ≥18 years.",
            "criterions": [
                {
                    "exact_snippets": "Age ≥18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Thyroid-stimulating hormone (TSH) ≤ institutional ULN",
            "criterions": [
                {
                    "exact_snippets": "Thyroid-stimulating hormone (TSH) ≤ institutional ULN",
                    "criterion": "Thyroid-stimulating hormone (TSH) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "institutional ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Candidate for neoadjuvant chemotherapy due to their clinical stage or subtype of breast cancer as decided by the treating physician.",
            "criterions": [
                {
                    "exact_snippets": "Candidate for neoadjuvant chemotherapy",
                    "criterion": "neoadjuvant chemotherapy candidacy",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "due to their clinical stage or subtype of breast cancer",
                    "criterion": "clinical stage or subtype of breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "suitability for neoadjuvant chemotherapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "as decided by the treating physician",
                    "criterion": "treating physician decision",
                    "requirements": [
                        {
                            "requirement_type": "approval",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Pathologically proven diagnosis of invasive breast cancer, cT1-T3, cN0-N3, cM0, HR+ (ER+ and/or PR+) HER2 negative or HR- (ER- and PR-) HER2 negative/triple negative breast cancer.",
            "criterions": [
                {
                    "exact_snippets": "Pathologically proven diagnosis of invasive breast cancer",
                    "criterion": "invasive breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "pathologically proven"
                        }
                    ]
                },
                {
                    "exact_snippets": "cT1-T3",
                    "criterion": "clinical tumor stage (T)",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "T"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "T"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "cN0-N3",
                    "criterion": "clinical nodal stage (N)",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "N"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "cM0",
                    "criterion": "clinical metastatic stage (M)",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": {
                                "operator": "=",
                                "value": 0,
                                "unit": "M"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "HR+ (ER+ and/or PR+) HER2 negative",
                    "criterion": "hormone receptor and HER2 status (HR+, HER2 negative)",
                    "requirements": [
                        {
                            "requirement_type": "hormone receptor status",
                            "expected_value": "positive (ER+ and/or PR+)"
                        },
                        {
                            "requirement_type": "HER2 status",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "HR- (ER- and PR-) HER2 negative/triple negative breast cancer",
                    "criterion": "hormone receptor and HER2 status (HR-, HER2 negative)",
                    "requirements": [
                        {
                            "requirement_type": "hormone receptor status",
                            "expected_value": "negative (ER- and PR-)"
                        },
                        {
                            "requirement_type": "HER2 status",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Systemic imaging with CT scan, bone scan, positron emission tomography (PET) scan or MRI if clinically indicated per treating physician's discretion.",
            "criterions": [
                {
                    "exact_snippets": "Systemic imaging with CT scan, bone scan, positron emission tomography (PET) scan or MRI",
                    "criterion": "systemic imaging",
                    "requirements": [
                        {
                            "requirement_type": "modality",
                            "expected_value": [
                                "CT scan",
                                "bone scan",
                                "positron emission tomography (PET) scan",
                                "MRI"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "if clinically indicated per treating physician's discretion",
                    "criterion": "clinical indication for imaging",
                    "requirements": [
                        {
                            "requirement_type": "determination",
                            "expected_value": "per treating physician's discretion"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* International normalized ratio (INR) and activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN. This applies to patients not receiving therapeutic anticoagulation. Patients on therapeutic anticoagulation should be on a stable dose.",
            "criterions": [
                {
                    "exact_snippets": "International normalized ratio (INR) ... ≤ 1.5 x ULN",
                    "criterion": "INR (International normalized ratio)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN",
                    "criterion": "aPTT (activated partial thromboplastin time)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "This applies to patients not receiving therapeutic anticoagulation",
                    "criterion": "therapeutic anticoagulation status",
                    "requirements": [
                        {
                            "requirement_type": "receiving therapeutic anticoagulation",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients on therapeutic anticoagulation should be on a stable dose",
                    "criterion": "therapeutic anticoagulation dose stability",
                    "requirements": [
                        {
                            "requirement_type": "dose stability",
                            "expected_value": "stable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Surgically sterile, or",
            "criterions": [
                {
                    "exact_snippets": "Surgically sterile",
                    "criterion": "surgical sterility",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women of childbearing age must use at least two adequate methods of contraception during the treatment period and at least 6 months from the last dose of chemotherapy. Examples of contraceptives include barrier methods, intrauterine devices (IUDs) hormonal or copper, oral contraceptive pills, and abstinence. Hormonal methods are not to be used by patients with HR+ breast cancer.",
            "criterions": [
                {
                    "exact_snippets": "Women of childbearing age must use at least two adequate methods of contraception during the treatment period and at least 6 months from the last dose of chemotherapy.",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "methods"
                            }
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": [
                                "during the treatment period",
                                "at least 6 months from the last dose of chemotherapy"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Hormonal methods are not to be used by patients with HR+ breast cancer.",
                    "criterion": "contraception method (hormonal) use in HR+ breast cancer patients",
                    "requirements": [
                        {
                            "requirement_type": "prohibition",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Postmenopausal for at least one year before the screening visit, or",
            "criterions": [
                {
                    "exact_snippets": "Postmenopausal for at least one year before the screening visit",
                    "criterion": "menopausal status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "postmenopausal"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Creatinine clearance of ≥ 30 mL/min",
            "criterions": [
                {
                    "exact_snippets": "Creatinine clearance of ≥ 30 mL/min",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC) ≥ 1500/µL",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) ≥ 1500/µL",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "/µL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Tumors with positive PD-L1 and/or PD-L1 protein expression. Positivity is defined as PD-L1 and/or PD-L2 expression of ≥ 1% of immune cells within the stroma or in cancer cells.",
            "criterions": [
                {
                    "exact_snippets": "positive PD-L1 and/or PD-L1 protein expression ... Positivity is defined as PD-L1 and/or PD-L2 expression of ≥ 1% of immune cells within the stroma or in cancer cells.",
                    "criterion": "PD-L1 expression",
                    "requirements": [
                        {
                            "requirement_type": "expression",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "cell_type",
                            "expected_value": [
                                "immune cells within the stroma",
                                "cancer cells"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "PD-L1 and/or PD-L2 expression of ≥ 1% of immune cells within the stroma or in cancer cells.",
                    "criterion": "PD-L2 expression",
                    "requirements": [
                        {
                            "requirement_type": "expression",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "cell_type",
                            "expected_value": [
                                "immune cells within the stroma",
                                "cancer cells"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be FEMALE",
            "criterions": [
                {
                    "exact_snippets": "Must be FEMALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin (Hb) ≥ 8g/dL",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin (Hb) ≥ 8g/dL",
                    "criterion": "hemoglobin (Hb) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. Patients must not have had a prior treatment for this breast cancer or for any malignancy diagnosed or treated within the past two years, with the exception of non-melanomatous skin cancer, carcinoma in situ of the cervix and contralateral breast cancer, as described above.",
            "criterions": [
                {
                    "exact_snippets": "must not have had a prior treatment for this breast cancer",
                    "criterion": "prior treatment for this breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "must not have had a prior treatment ... for any malignancy diagnosed or treated within the past two years",
                    "criterion": "prior treatment for any malignancy diagnosed or treated within the past two years",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "with the exception of non-melanomatous skin cancer, carcinoma in situ of the cervix and contralateral breast cancer",
                    "criterion": "exceptions to prior malignancy exclusion",
                    "requirements": [
                        {
                            "requirement_type": "exception_list",
                            "expected_value": [
                                "non-melanomatous skin cancer",
                                "carcinoma in situ of the cervix",
                                "contralateral breast cancer"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. HER2/neu must be negative by immunohistochemistry (IHC) defined as IHC 0 or 1+ or fluorescence in situ hybridization (FISH) or other ISH methods with a ratio of < 2 according to current ASCO (American Society of Clinical Oncology)/CAP guidelines.",
            "criterions": [
                {
                    "exact_snippets": "HER2/neu must be negative by immunohistochemistry (IHC) defined as IHC 0 or 1+",
                    "criterion": "HER2/neu status by immunohistochemistry (IHC)",
                    "requirements": [
                        {
                            "requirement_type": "IHC score",
                            "expected_value": [
                                "0",
                                "1+"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "HER2/neu must be negative by ... fluorescence in situ hybridization (FISH) or other ISH methods with a ratio of < 2",
                    "criterion": "HER2/neu status by FISH or other ISH methods",
                    "requirements": [
                        {
                            "requirement_type": "ratio",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3x institutional upper limit of normal (ULN)",
            "criterions": [
                {
                    "exact_snippets": "Alanine aminotransferase (ALT) ... ≤ 3x institutional upper limit of normal (ULN)",
                    "criterion": "alanine aminotransferase (ALT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "aspartate aminotransferase (AST) ≤ 3x institutional upper limit of normal (ULN)",
                    "criterion": "aspartate aminotransferase (AST)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet count ≥ 100,000/µL",
            "criterions": [
                {
                    "exact_snippets": "Platelet count ≥ 100,000/µL",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "/µL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. The patient must provide study-specific informed consent prior to study entry.",
            "criterions": [
                {
                    "exact_snippets": "The patient must provide study-specific informed consent prior to study entry.",
                    "criterion": "study-specific informed consent",
                    "requirements": [
                        {
                            "requirement_type": "provision",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to study entry"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Estrogen and/or progesterone receptor positive tumor defined ≥1% positively staining cells by immunohistochemistry, according to the current American Society of Clinical Oncology (ASCO) / College of American Pathologists (CAP) guidelines.",
            "criterions": [
                {
                    "exact_snippets": "Estrogen and/or progesterone receptor positive tumor defined ≥1% positively staining cells by immunohistochemistry",
                    "criterion": "estrogen receptor status",
                    "requirements": [
                        {
                            "requirement_type": "positivity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "positively staining cells by immunohistochemistry",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "guideline",
                            "expected_value": "according to the current American Society of Clinical Oncology (ASCO) / College of American Pathologists (CAP) guidelines"
                        }
                    ]
                },
                {
                    "exact_snippets": "Estrogen and/or progesterone receptor positive tumor defined ≥1% positively staining cells by immunohistochemistry",
                    "criterion": "progesterone receptor status",
                    "requirements": [
                        {
                            "requirement_type": "positivity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "positively staining cells by immunohistochemistry",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "guideline",
                            "expected_value": "according to the current American Society of Clinical Oncology (ASCO) / College of American Pathologists (CAP) guidelines"
                        }
                    ]
                }
            ]
        },
        {
            "line": "16. Patients with multicentric or multifocal disease are eligible if they are a candidate for neoadjuvant chemotherapy.",
            "criterions": [
                {
                    "exact_snippets": "Patients with multicentric or multifocal disease",
                    "criterion": "multicentric or multifocal disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "if they are a candidate for neoadjuvant chemotherapy",
                    "criterion": "candidate for neoadjuvant chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum bilirubin within ≤ 1.5 x ULN except patients with Gilbert's syndrome for whom the direct bilirubin should be within normal range.",
            "criterions": [
                {
                    "exact_snippets": "Serum bilirubin within ≤ 1.5 x ULN",
                    "criterion": "serum bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except patients with Gilbert's syndrome for whom the direct bilirubin should be within normal range",
                    "criterion": "direct bilirubin (in patients with Gilbert's syndrome)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": "within normal range"
                        }
                    ]
                }
            ]
        },
        {
            "line": "15. Patients with bilateral breast cancer are also eligible provided HER2 negativity is documented on both right and left breast cancer and patient is deemed to be a candidate for neoadjuvant chemotherapy by treating physician.",
            "criterions": [
                {
                    "exact_snippets": "Patients with bilateral breast cancer are also eligible",
                    "criterion": "bilateral breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "HER2 negativity is documented on both right and left breast cancer",
                    "criterion": "HER2 status of breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "laterality",
                            "expected_value": [
                                "right",
                                "left"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "patient is deemed to be a candidate for neoadjuvant chemotherapy by treating physician",
                    "criterion": "candidate for neoadjuvant chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "physician assessment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Breast imaging with mammogram and/or ultrasound and/or MRI is per standard of care for diagnosis, but at least one modality of imaging must be completed within 30 days of registration.",
            "criterions": [
                {
                    "exact_snippets": "at least one modality of imaging must be completed within 30 days of registration",
                    "criterion": "breast imaging",
                    "requirements": [
                        {
                            "requirement_type": "completion",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "modality_count",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "modality"
                            }
                        },
                        {
                            "requirement_type": "time_window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If they are of childbearing potential, negative pregnancy test within 14 calendar days prior to registration for women of childbearing potential",
            "criterions": [
                {
                    "exact_snippets": "If they are of childbearing potential",
                    "criterion": "childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "negative pregnancy test within 14 calendar days prior to registration for women of childbearing potential",
                    "criterion": "pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "calendar days prior to registration"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "1. Patients with clinical or pathologically proven metastatic disease.",
            "criterions": [
                {
                    "exact_snippets": "clinical or pathologically proven metastatic disease",
                    "criterion": "metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "clinical",
                                "pathological"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. History of symptomatic CHF⎯Grade ≥ 3 per NCI CTCAE v5.0 or New York Heart Association (NYHA) Class ≥ II.",
            "criterions": [
                {
                    "exact_snippets": "History of symptomatic CHF⎯Grade ≥ 3 per NCI CTCAE v5.0",
                    "criterion": "symptomatic congestive heart failure (CHF)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity grade (NCI CTCAE v5.0)",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of symptomatic CHF ... New York Heart Association (NYHA) Class ≥ II",
                    "criterion": "symptomatic congestive heart failure (CHF)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "NYHA class",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "class"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Treatment with any investigational drug within 30 days of registration. Prior treatment with any immunotherapy or chemotherapy for this breast cancer.",
            "criterions": [
                {
                    "exact_snippets": "Treatment with any investigational drug within 30 days of registration",
                    "criterion": "treatment with investigational drug",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "timing_reference",
                            "expected_value": "of registration"
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with any immunotherapy or chemotherapy for this breast cancer",
                    "criterion": "prior treatment for this breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "treatment_type",
                            "expected_value": [
                                "immunotherapy",
                                "chemotherapy"
                            ]
                        },
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Purely noninvasive breast cancer (i.e., ductal carcinoma in situ, lobular carcinoma in situ) without any concurrent invasive breast cancer",
            "criterions": [
                {
                    "exact_snippets": "Purely noninvasive breast cancer (i.e., ductal carcinoma in situ, lobular carcinoma in situ)",
                    "criterion": "breast cancer type",
                    "requirements": [
                        {
                            "requirement_type": "histology",
                            "expected_value": [
                                "ductal carcinoma in situ",
                                "lobular carcinoma in situ"
                            ]
                        },
                        {
                            "requirement_type": "invasiveness",
                            "expected_value": "noninvasive"
                        }
                    ]
                },
                {
                    "exact_snippets": "without any concurrent invasive breast cancer",
                    "criterion": "concurrent invasive breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Cardiopulmonary dysfunction defined as: Inadequately controlled angina, heart failure or serious cardiac arrhythmia not controlled by adequate medication.",
            "criterions": [
                {
                    "exact_snippets": "Inadequately controlled angina",
                    "criterion": "angina",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "inadequately controlled"
                        }
                    ]
                },
                {
                    "exact_snippets": "heart failure",
                    "criterion": "heart failure",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "serious cardiac arrhythmia not controlled by adequate medication",
                    "criterion": "serious cardiac arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "not controlled by adequate medication"
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Pregnant or lactating women are ineligible.",
            "criterions": [
                {
                    "exact_snippets": "Pregnant ... are ineligible",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnancy",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "lactating women are ineligible",
                    "criterion": "lactation status",
                    "requirements": [
                        {
                            "requirement_type": "lactation",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with controlled Type 1 diabetes mellitus on a stable insulin regimen are eligible for this study.",
            "criterions": [
                {
                    "exact_snippets": "Patients with controlled Type 1 diabetes mellitus",
                    "criterion": "Type 1 diabetes mellitus",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "control status",
                            "expected_value": "controlled"
                        }
                    ]
                },
                {
                    "exact_snippets": "on a stable insulin regimen",
                    "criterion": "insulin regimen",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "stable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Synchronous non-breast malignancy (exceptions include non-melanomatous skin cancer, carcinoma in situ of the cervix).",
            "criterions": [
                {
                    "exact_snippets": "Synchronous non-breast malignancy",
                    "criterion": "synchronous non-breast malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "exceptions include non-melanomatous skin cancer, carcinoma in situ of the cervix",
                    "criterion": "non-melanomatous skin cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "exceptions include non-melanomatous skin cancer, carcinoma in situ of the cervix",
                    "criterion": "carcinoma in situ of the cervix",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "15. Treatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor (TNF) agents) within 2 weeks prior to study entry, or anticipated requirement for systemic immunosuppressive medications during the study. Patients who have received acute, low-dose, systemic immunosuppressant medications equivalent to ≤ 10mg of prednisone within the 7 days prior to study entry (small dose of dexamethasone for nausea, short course for upper respiratory tract infection etc.) may be enrolled in the study.",
            "criterions": [
                {
                    "exact_snippets": "Treatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor (TNF) agents) within 2 weeks prior to study entry",
                    "criterion": "systemic corticosteroid or systemic immunosuppressive medication use",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "anticipated requirement for systemic immunosuppressive medications during the study",
                    "criterion": "anticipated requirement for systemic immunosuppressive medications",
                    "requirements": [
                        {
                            "requirement_type": "anticipated use during study",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients who have received acute, low-dose, systemic immunosuppressant medications equivalent to ≤ 10mg of prednisone within the 7 days prior to study entry",
                    "criterion": "acute, low-dose, systemic immunosuppressant medication use",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "mg prednisone equivalent"
                            }
                        },
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Current grade ≥ 2 peripheral neuropathy (according to NCI CTCAE v. 5.0).",
            "criterions": [
                {
                    "exact_snippets": "Current grade ≥ 2 peripheral neuropathy (according to NCI CTCAE v. 5.0)",
                    "criterion": "peripheral neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "severity_grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "NCI CTCAE v. 5.0"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Positive test for HIV.",
            "criterions": [
                {
                    "exact_snippets": "Positive test for HIV",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. HER2 positive disease as determined by either ISH or 3+ on IHC.",
            "criterions": [
                {
                    "exact_snippets": "HER2 positive disease as determined by either ISH or 3+ on IHC",
                    "criterion": "HER2 status",
                    "requirements": [
                        {
                            "requirement_type": "positivity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "determination method",
                            "expected_value": [
                                "ISH",
                                "IHC 3+"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible for this study.",
            "criterions": [
                {
                    "exact_snippets": "history of autoimmune-related hypothyroidism",
                    "criterion": "autoimmune-related hypothyroidism",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "on a stable dose of thyroid replacement hormone",
                    "criterion": "thyroid replacement hormone",
                    "requirements": [
                        {
                            "requirement_type": "dose stability",
                            "expected_value": "stable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "14. History of autoimmune disease, including but not limited to myasthenia gravis, autoimmune myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.",
            "criterions": [
                {
                    "exact_snippets": "History of autoimmune disease",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "myasthenia gravis",
                    "criterion": "myasthenia gravis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "autoimmune myositis",
                    "criterion": "autoimmune myositis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "autoimmune hepatitis",
                    "criterion": "autoimmune hepatitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "systemic lupus erythematosus",
                    "criterion": "systemic lupus erythematosus",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "rheumatoid arthritis",
                    "criterion": "rheumatoid arthritis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "inflammatory bowel disease",
                    "criterion": "inflammatory bowel disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "vascular thrombosis associated with antiphospholipid syndrome",
                    "criterion": "vascular thrombosis associated with antiphospholipid syndrome",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Wegener granulomatosis",
                    "criterion": "Wegener granulomatosis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Sjögren's syndrome",
                    "criterion": "Sjögren's syndrome",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Guillain-Barré syndrome",
                    "criterion": "Guillain-Barré syndrome",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "multiple sclerosis",
                    "criterion": "multiple sclerosis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "vasculitis",
                    "criterion": "vasculitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "glomerulonephritis",
                    "criterion": "glomerulonephritis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Medical, psychiatric or other conditions that would prevent the patient from receiving the protocol therapy or providing informed consent.",
            "criterions": [
                {
                    "exact_snippets": "Medical, psychiatric or other conditions that would prevent the patient from receiving the protocol therapy",
                    "criterion": "medical, psychiatric, or other conditions",
                    "requirements": [
                        {
                            "requirement_type": "impact on protocol therapy",
                            "expected_value": "would prevent the patient from receiving the protocol therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "Medical, psychiatric or other conditions that would prevent the patient from ... providing informed consent",
                    "criterion": "medical, psychiatric, or other conditions",
                    "requirements": [
                        {
                            "requirement_type": "impact on informed consent",
                            "expected_value": "would prevent the patient from providing informed consent"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis) are eligible, provided the disease has no systemic manifestations and requires only low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%).",
            "criterions": [
                {
                    "exact_snippets": "Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only",
                    "criterion": "eczema, psoriasis, lichen simplex chronicus, or vitiligo",
                    "requirements": [
                        {
                            "requirement_type": "manifestation type",
                            "expected_value": "dermatologic only"
                        }
                    ]
                },
                {
                    "exact_snippets": "provided the disease has no systemic manifestations",
                    "criterion": "systemic manifestations of eczema, psoriasis, lichen simplex chronicus, or vitiligo",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "requires only low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%)",
                    "criterion": "treatment for eczema, psoriasis, lichen simplex chronicus, or vitiligo",
                    "requirements": [
                        {
                            "requirement_type": "treatment type",
                            "expected_value": "low potency topical steroids"
                        },
                        {
                            "requirement_type": "treatment examples",
                            "expected_value": [
                                "hydrocortisone 2.5%",
                                "hydrocortisone butyrate 0.1%",
                                "fluocinolone 0.01%",
                                "desonide 0.05%",
                                "alclometasone dipropionate 0.05%"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Men with breast cancer. Male breast cancer is a rare event.",
            "criterions": [
                {
                    "exact_snippets": "Men with breast cancer",
                    "criterion": "sex and breast cancer diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "male"
                        },
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": "breast cancer"
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Active Hepatitis B defined as positive Hep B surface antigen (HBsAg) or Hepatitis C. Patients with previous hepatitis B virus (HBV) infection or resolved HBV infection (defined as having a negative HBsAg test and a positive antibody to hepatitis B core antigen [anti-HBc] antibody test) are eligible. If HBV DNA testing is positive, the patient is not eligible for study participation. Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.",
            "criterions": [
                {
                    "exact_snippets": "Active Hepatitis B defined as positive Hep B surface antigen (HBsAg)",
                    "criterion": "Hepatitis B surface antigen (HBsAg)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Hepatitis C",
                    "criterion": "Hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "If HBV DNA testing is positive, the patient is not eligible for study participation.",
                    "criterion": "HBV DNA",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.",
                    "criterion": "HCV RNA (by PCR)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}